Predictors of Pain Reduction in Trials of Interventions for Aromatase Inhibitor–Associated Musculoskeletal Symptoms

BACKGROUND: Almost one-half of aromatase inhibitor (AI)–treated breast cancer patients experience AI-associated musculoskeletal symptoms (AIMSS); 20%-30% discontinue treatment because of severe symptoms. We hypothesized that we could identify predictors of pain reduction in AIMSS intervention trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Henry, N Lynn, Unger, Joseph M, Till, Cathee, Crew, Katherine D, Fisch, Michael J, Hershman, Dawn L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660068/
https://www.ncbi.nlm.nih.gov/pubmed/34901744
http://dx.doi.org/10.1093/jncics/pkab087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660068/
https://www.ncbi.nlm.nih.gov/pubmed/34901744
http://dx.doi.org/10.1093/jncics/pkab087

Ejemplares similares